STAR Strides Pharma Science Q1 FY26 results (Apr–Jun 2025) and concall
Strides Pharma delivered a strong Q1 FY26, reporting ₹1,120 crores in revenue, driven by robust profitability with gross margins at 60% and EBITDA at 19.5%. The company continued its focus on efficiency, reducing net debt to ₹1,496 crores. While US sales saw a seasonal Q-o-Q dip and the access market faced donor funding challenges, management expressed confidence in accelerating growth from Q2 and its long-term 'beyond generics' strategy.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 520 | 551 | 556 | 499 |
| EBITDA | 55 | 74 | 68 | 67 |
| Net profit | 17 | 15 | 16 | 13 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
